How is Suboxone (buprenorphine and naloxone) normally dispensed, does it come with refills and what is the typical supply duration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 28, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Suboxone Dispensing Practices

Suboxone (buprenorphine/naloxone) is typically dispensed as a 30-day supply with refills allowed, unlike methadone which requires daily clinic visits for most patients. This office-based prescribing model makes buprenorphine treatment more accessible and acceptable to patients who would not attend traditional opioid maintenance clinics 1.

Standard Dispensing Protocol

Initial Prescription

  • Prescribers can write prescriptions for Suboxone that patients fill at retail pharmacies, distinguishing it from methadone's clinic-based dispensing model 1
  • The typical therapeutic dose range is 8-16 mg daily, with a target of 16 mg for most patients 2
  • Suboxone contains buprenorphine and naloxone in a 4:1 ratio (e.g., 8 mg buprenorphine/2 mg naloxone) 3, 4

Supply Duration and Refills

  • Standard practice allows for 30-day supplies with refills, enabling less frequent clinic visits compared to methadone programs 2
  • Less frequent dispensing (e.g., thrice weekly) does not compromise efficacy and can improve patient satisfaction 3
  • For patients with stable opioid use disorder in remission who demonstrate good adherence, weekly "pickups" or "take homes" may be appropriate 5

Formulation Selection

Suboxone (Buprenorphine/Naloxone) - Preferred for Most Patients

  • The American Academy of Family Physicians recommends buprenorphine/naloxone as the preferred formulation due to safety features that prevent misuse by crushing and injecting 2
  • The naloxone component has relatively low sublingual bioavailability and exerts no clinically significant effect when taken as prescribed 3, 6
  • When parenterally administered, naloxone causes withdrawal effects in opioid-dependent patients, reducing abuse potential 3

Subutex (Buprenorphine Alone) - Special Circumstances

  • May be preferred for pregnancy, documented naloxone allergy, or patients with severe chronic pain requiring divided doses 2
  • Subutex is specifically recommended for pregnant women to avoid naloxone exposure 1

Dosing Schedules

Standard Maintenance Dosing

  • Once-daily dosing is standard for opioid use disorder maintenance 2
  • Sublingual tablets typically disintegrate in 6-12 minutes 4
  • Plasma concentrations decline bi-exponentially with a terminal half-life of approximately 26 hours (range 9-69 hours) 4

Divided Dosing for Pain Management

  • For chronic pain management, buprenorphine can be prescribed off-label in split doses (every 6-8 hours) 5, 2
  • Dosing ranges of 4-16 mg divided into 8-hour doses have shown benefit in patients with chronic non-cancer pain 5

Critical Dispensing Considerations

Preventing Precipitated Withdrawal

  • Suboxone should only be dispensed to patients in active opioid withdrawal 2, 7
  • Required waiting periods before first dose: short-acting opioids >12 hours, extended-release formulations >24 hours, methadone >72 hours 2, 7
  • Use the Clinical Opiate Withdrawal Scale (COWS) to confirm withdrawal severity before dispensing 2, 7

Monitoring Requirements

  • Regular urine drug testing to assess for continued illicit opioid use 2
  • Hepatitis C and HIV screening as part of comprehensive care 2, 7
  • Assess for opioid use disorder using DSM-5 criteria during follow-up visits 2

Common Pitfall to Avoid

Never dispense or administer buprenorphine while patients are still under the influence of full opioid agonists, as this will precipitate severe withdrawal due to buprenorphine's high receptor affinity displacing other opioids 2, 7. This is the most critical safety consideration in Suboxone dispensing.

References

Research

Buprenorphine in the treatment of opiate dependence.

Journal of psychoactive drugs, 2010

Guideline

Buprenorphine Therapy for Opioid Addiction

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Buprenorphine Withdrawal Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.